Evidence map›Paper›PMID 16034885›Full record

SynthesisThe Cochrane database of systematic reviews2005

Once versus twice daily LMWH for the initial treatment of venous thromboembolism.

C J van Dongen, M R MacGillavry, M H Prins

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03353311 (ERAS Lazio Network Clinical Registry), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03353311 completednot on this mapstarted 2014, after this paper: background citation

ERAS Lazio Network Clinical Registry

Typeobservational_patient_registrySponsorPERSIANI ROBERTORan2014 to 2017Enrolled1,000ConditionsColon Cancer, Diverticulum, Colon
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Article
  4. Review
  5. Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

C J van DongenDepartment of Clinical Epidemiology and Biostatistics, Room J2-204, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, Netherlands. c.j.vandongen@amc.uva.nl
M R MacGillavry
M H Prins

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen.

objectivesTo compare the efficacy and safety of once daily versus twice daily administration of LMWH. SEARCH STRATEGY: We identified trials through searching the Specialised Register of the Cochrane Peripheral Vascular Diseases Group (last searched April 2005), the Cochrane Central Controlled Trials Register (CENTRAL) (last searched Issue 2, 2005), handsearches of relevant journals, checking cross-references and through personal communication with experts. SELECTION CRITERIA: Randomised clinical trials in which LMWH given once daily is compared to LMWH given twice daily for the initial treatment of venous thromboembolism. DATA COLLECTION AND ANALYSIS: Two authors assessed trials for inclusion and extracted data independently. MAIN

resultsFive studies were included with a total of 1508 participants. The pooled data showed a statistically non-significant difference in recurrent venous thromboembolism between the two treatment regimens (OR 0.82, 0.49 to 1.39). A comparison of major haemorrhagic events (OR 0.77, 0.40 to 1.45) and mortality (OR 1.14, 0.62 to 2.08) also showed a statistically non-significant difference between the two treatment regimens. AUTHORS'

conclusionsOnce daily treatment with LMWH is as effective and safe as twice daily treatment with LMWH. However, the 95% confidence interval implies that there is a possibility that the risk of recurrent VTE might be higher when people are treated once daily. Hence, the decision to treat a person with a once daily regimen will depend on the evaluated balance between increased convenience and the potential for a lower efficacy.

Indexed as

AnticoagulantsDrug Administration ScheduleHemorrhageHeparin, Low-Molecular-WeightHumansPulmonary EmbolismRandomized Controlled Trials as TopicThromboembolismVenous ThrombosisAnticoagulantsHeparin, Low-Molecular-Weight

Identifiers

PMID16034885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.